Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Healx secures option to license rights from Ovid to develop gaboxadol
As per the agreement, Healx intends to investigate the compound as part of a potential combination therapy for Fragile X syndrome and treatment for other indications. Fragile X
As per the agreement, Healx intends to investigate the compound as part of a potential combination therapy for Fragile X syndrome and treatment for other indications. Fragile X
The drug attaches to a specific protein on the cancer cells’ surface and helps the immune system to detect and attack them. Approximately 100 women with advanced and
Enjaymo is intended to reduce the need for red blood cell transfusion caused due to hemolysis in CAD patients. The drug is a humanised monoclonal antibody that selectively
As part of the collaboration, Janssen will provide its antibodies and Mersana will apply its Dolasynthen platform and expertise for the discovery of the new ADC product candidates.
As part of the collaboration, both the companies will co-develop AVT23, an investigational compound, that is now in late development stage. The companies will develop the proposed biosimilar
Cabenuva has now been cleared for every-two-month dosing for the treatment of HIV-1 in people who are virologically suppressed on a stable regimen, with no prior treatment failure,
The protein-based vaccine candidate is intended to immunise individuals aged 18 years and above against Covid-19. Developed using Novavax’ recombinant nanoparticle technology, NVX-CoV2373 is engineered from the genetic
The drug is intended to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) in
The biopharmaceutical company stated that the dormant vaccine manufacturing site would add new capabilities to its medicine portfolio of Canadian and US companies. It is expected to allow
The US regulator has accepted the company’s supplemental new drug application (sNDA) for Evrysdi to treat SMA in pre-symptomatic babies, aged below two months. Evrysdi is a survival